NDAINHALATIONAEROSOL, METERED
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
BREZTRI AEROSPHERE (budesonide, glycopyrrolate, and formoterol fumarate) by AstraZeneca is adrenergic beta2-agonists [moa]. Approved for beta2-adrenergic agonist [epc]. First approved in 2020.
Drug data last refreshed 15h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BREZTRI AEROSPHERE is a triple-combination inhaled corticosteroid (budesonide), long-acting muscarinic antagonist (glycopyrrolate), and long-acting beta-2 agonist (formoterol fumarate) approved for maintenance treatment of COPD. It works by reducing airway inflammation, improving airflow, and decreasing mucus production. The product combines three distinct pharmacologic mechanisms in a single metered-dose aerosol formulation.
$0.796BPart D
Peak12.2 years to LOEStrong commercial phase with $796M in Part D spending (2023) and nearly 1M patient claims indicates a well-established franchise with significant team infrastructure supporting commercial execution.
Mechanism of Action
Adrenergic beta2-Agonists
Pharmacologic Class:
beta2-Adrenergic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease
Started Jan 2026
150 enrolled
Moderate to Severe COPD
Why This Matters for Your Career
Worked on BREZTRI AEROSPHERE at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.